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Abstract
Monoaminergic antidepressants have a delay in the onset of response 
that needs alternatives. Sub anesthetic doses of ketamine, a NMDA receptor 
antagonist, show a rapid-acting antidepressant effect in Major Depressive 
Disorder (MDD) and in bipolar depression, and improve suicidal ideation. 
However, for ketamine routinely use as antidepressant, more clinical research 
on the relation risks and benefits is needed to decide if ketamine is a promise 
or a reality.
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depression within the first week of treatment [26]. However, clinical 
experience with this agent is limited.
On the other hand, some non-pharmacological interventions, as 
Electroconvulsive Therapy (ECT), repetitive transcranial magnetic 
stimulation (rTMS), Deep Brain Stimulation (DBS) as well as 
“sleep deprivation” showed promising results on early response in 
depression, but these results needs to be confirmed with controlled 
clinical trials [6].
Ketamine: A non-monoaminergic pathway for fast 
antidepressant response 
Rapid antidepressant response will require alternative mechanisms 
of action to “the monoamine hypothesis” [2,4,6]. Glutamatergic 
system has been shown to be a key pathway in the pathophysiology 
of a variety of central nervous diseases including MDD [4,27]. In 
fact, different antidepressants, as Monoamine-Oxidase Inhibitors 
(MAOIs), Selective Serotonin Reuptake Inhibitors (SSRIs), tricyclic 
antidepressants, desensitize the locus of glycine in NMDA receptors, 
down-regulating glutamatergic neurotransmission. This effect was 
the most sensitive predictor of antidepressant activity [28]. Moreover, 
NMDA receptor antagonists, as amantadine, or D-cycloserine, has 
provided conceptual, but limited, clinical support for glutamatergic 
hypothesis of depression [29,30]. 
Ketamine, a dissociative anesthetic with hallucinogens 
properties, is a non-selective non-competitive high affinity of 
ionotropicglutamatergic NMDA receptors antagonist [31], that 
show a complex pharmacodynamic profile. Ketamine show 
preclinical antidepressant response in some predictive tasks [32,33]. 
Ketamine act primarily as NMDA antagonist and also interact with 
monoamine, nicotinic and muscarinic cholinergic receptors and 
opioids receptors [31,34]. Antagonism at NMDA receptor triggers 
a cascade of events responsible for the antidepressant response to 
ketamine. Thus, ketamine blocking primarily NMDA receptors 
increase glutamate synthesis and release that stimulate postsynaptic 
Introduction
Major Depressive Disorder (MDD) is one of the most prevalent, 
serious and debilitating forms of mental illness with health, 
socioeconomic and familiar consequences [1]. In the last six decades, 
agents that modulate monoaminergic systems are widely used as 
antidepressants. However, these are limited in terms of overall 
efficacy and in the delay in the onset of antidepressant response [2-4]. 
Delay in antidepressant effect increase morbidity, suicidal ideation 
[5], psychosocial defeat, quality of life loss [6] and non adherence to 
treatment [7]. 
For these reasons, there is a growing interest in rapid-onset 
pharmacological alternatives [2].To carry out this mini-review, 
literature was retrieved (July 2014) from PubMed.gov and 
bibliographic funds of the Alcala University Library, using the 
keywords ketamine, rapid, fast or early antidepressant effect. 
Current and past strategies to accelerate therapeutic 
response in depression
In despite that some meta-analysis [8-10], showed an 
improvement in the first week of classical and modern antidepressant 
treatment [6-11], response rates were generally small [6], not affect 
the core symptoms of depression and severe melancholic depression 
do not showed rapid response. An early antidepressant effect may 
be an artifact [12]. Thus, with very little controversy [6-11], a delay 
in antidepressant response for more than two weeks is generally 
accepted [2,3,7,13].
In order to try a rapid antidepressant response, agents not 
classified as antidepressants, as pindolol [14,15], mifepristone [16], 
metyrapone [17], methylphenidate [18,19], Thyrotropin-Releasing 
Hormone (TRH) [20,21],have been investigated with promising 
initial results but with limited clinical success. Recently, agomelatine, 
a melatonergic receptor agonist, with a non-monoaminergic profile 
[22-25], showed significant improvements in the core symptoms of 
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AMPA receptor. This stimulation increase expression of Akt/mTOR 
pathway (mammalian target of rapamycin) [35,36] and Brain-Derived 
Neurotrophic Factor (BDNF) [37]. These proteins are associated 
with neuronal growth, differentiation, synaptic plasticity, and 
general functioning of the neuron. Furthermore, ketamine has been 
shown to inhibit brain GSK-3 [38,39], a kinase that is also a target 
of mood stabilizing agents. Moreover, in the rapid mood elevation 
can be implicated the anti-inflammatory activity [40] or inhibition 
of nitric oxide synthesis [31] induced by ketamine. Thus, blockade of 
NMDA receptors by ketamine trigger AMPA receptors stimulation 
that seems to be essential for its antidepressant effects. In fact, AMPA 
receptor antagonists block ketamine antidepressant effects in animal 
models [29,31,41]. 
Ketamine: A prototype for rapid-acting antidepressant in 
depressed patients
The seminal study of Berman et al. was the first to show that 
a single low sub-anesthetic ketamine IV infusion (0.5 mg/kg/40 
min.) produces a rapid antidepressant response within 4 hours that 
persist for at least 3 days [30]. Ketamine improve core symptoms 
of depression and these effects are disconnected from euphoria or 
“high” induced by this agent [30].These findings were replicated in 18 
patients with treatment-resistant depression, which reported a more 
rapid response within 2 hours that persist for 7 days [42]. Several 
open and controlled trials confirm the rapid antidepressant actions 
of single infusion of ketamine [5,6,31,43]. Murrough et al. carry out 
the largest (n=73) randomized controlled trial of a single infusion of 
ketamine to date [44]. Ketamine, in comparison with midazolam, 
show a rapid and broad-spectrum antidepressant effect (response 
rates: 64% and 28% respectively). Ketamine, independently of 
antidepressant effect, reversed suicidal ideation. On the other hand, 
ketamine showed positive results in bipolar depression [45,46] and 
had significant efficacy in patients resistant to ECT [47].
Moreover, the efficacy of repeated administration of ketamine has 
been studied. Aan het Rot et al. showed significant improvement of 
symptoms following six infusions of ketamine over 11 days, although 
the 9 patients treated in this trial eventually relapsed 19 days after 
the final infusion [48]. These results were replicated by Murrough et 
al. in 24 patients with resistant depression. The overall response rate 
at study end was 70.8%. Among responders, median time to relapse 
following the last ketamine infusion was 18 days [49]. Recently, 
antidepressant effects were obtained in an open trial using repeated 
ketamine as augmenter in twelve patients that maintain stable doses 
of antidepressant regimen [50].
On the other hand, ketamine improve mood level and was well 
tolerated by intramuscular [51], sublingual [52] or intranasal [53,54] 
administration. Oral administration of ketamine improves depressive 
symptoms at day 14 of treatment [55]. These data open the option 
for a more practical use of ketamine, but more controlled studies are 
needed. 
Clinical evidence support that low doses of single or repetitive 
ketamine infusion have a rapid-acting antidepressant effect in MDD 
and in bipolar depression and improve suicidal ideation. These effects 
were independent from euphoria or “high” induced by this agent. 
Ketamine superiority over standard antidepressants is unequivocal. 
The response rates with ketamine at 24 and 72 hours is superior to 
obtain with traditional monoaminergic antidepressants at 6-8 weeks 
of treatment [43,56]. However, many of the discussed studies in this 
review are methodological limited in regard to their sample size. 
A sample size of 102, 51 in each group, would be required within 
randomized controlled trials methodology to detect a moderate effect 
size of 0.5, with a power of 80% and 0.05 significance. But, none 
included a sample size in this size. The study by Murroughet al. [44] 
was the largest to date but still included only 47 patients treated with 
ketamine. Moreover, despite the fact that some clinical trials were 
made with the technique of double-blind, caution must therefore be 
taken in interpreting these results, although several authors identified 
the difficulties in blinding ketamine administration [43].
Safety profile of ketamine and risk-benefits relation
Routinely use of ketamine as antidepressant can be considered 
only when tolerability and safety in humans will be established. 
At this moment, ketamine has a long track record of safety when 
administered as a surgical anesthetic [57]. However, less is known 
about single and repetitive infusion at sub anesthetic doses in less 
intensively monitored depressed patients. On the other hand, 
generalize the results of clinical trials to practice daily is difficult due 
to the restrictive criteria of exclusion, as acute suicidal risk, history 
of psychosis, unstable general medical conditions, substance abuse, 
abnormal ECGs, applied in studies [58].
Ketamine is one of several “club drugs” that is abused. Misuse of 
therapeutically relevant agents is a risk but not a new phenomenon 
in psychiatry (i.e. anticholinergic drugs, stimulants, benzodiazepines, 
opioids) and should not preclude their study as putative treatments 
[59].
In antidepressant clinical trials, the dissociative profile of 
ketamine, as perceptual disturbances, confusion, euphoria, dizziness 
and increased libido, appears to be similar to that observed in healthy 
subjects and ceased within 2hours following the infusion. Interesting, 
in clinical trials of MDD or bipolar patients, ketamine has not led the 
transition to mania [29,44,49,60].
Ketamine abuse is related with neural injuries, cognitive 
impairments, altered thought content as well as alteration of 
mnemonic functions [31,61,62]. Thus, testing the impact of chronic 
ketamine on these items in longer-term controlled studies is critical.
Distressing adverse events following ketamine infusion, as 
anxiety, might raise the risk of suicidal thinking [58] but clinical 
trials to date [43,44,49] support the premise that ketamine has rapid 
beneficial effects on suicidal cognition. However, this important issue 
will need careful prospective study in larger samples.
Although somatic adverse effects have generally been mild, 33% 
of patients have experienced brief changes in blood pressure and/or 
heart rate and two subjects required their infusions to be stopped for 
hemodynamic reasons [49]. Thus cardio respiratory monitoring is an 
essential component of risk management.
On the other hand, experimental and clinical reports of long-
term ketamine induced ulcerative cystitis, increased frequencies of 
bladder carcinoma and kidney dysfunction need to be controlled with 
the repeated use of ketamine [31,59].
However, if these findings with ketamine could be directly 
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compared with monoaminergic antidepressants, ketamine represent 
some advantages [28]. Thus, considering these methodological 
limitations, ketamine has shown evidence that it is safe for the 
treatment of depression [29]. 
Conclusion
Current ketamine research has been shown that significant clinical 
improvement in depression symptoms may occur within hours of drug 
administration. Moreover, ketamine show that a rapid antidepressant 
effect can be found beyond the monoaminergic mechanisms of 
current antidepressant medications that required weeks to months to 
produce benefits in responding patients. Ketamine is a promising tool 
to learn more about the pathophysiology of depression and develop 
more specific rapid-acting antidepressant treatments.
The literature demonstrates evidence supporting that a 
single intravenous sub anesthetic dose of ketamine exerts rapid 
antidepressant effects in patients with MDD, bipolar depression and 
reduces suicidal ideation.
Apparently, safety concerns associated with ketamine dictate 
a cautious approach to its application outside of research and 
more clinical research on the risks and benefits of ketamine 
use is indispensable. At this moment, in despite of tremendous 
excitement create by ketamine, their administration is not routinely 
recommended [58,63].
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